Insulin-like growth factor 2 in paediatric gliomas:

expression, intracellular localization and association with clinical outcome

<u>Florencia Clément¹, Ayelen Martin¹, Marcela Venara¹, María Celia Fernández¹, Mercedes García Lombardi², Ignacio Bergadá¹, Patricia Pennisi¹</u>

¹Centro de Investigaciones Endocrinológicas "Dr. César Bergadá", (CEDIE) CONICET – FEI – División de Endocrinología, Hospital de Niños "Ricardo Gutiérrez", Buenos Aires, Argentina. ²Servicio de Oncología, Hospital de Niños "Dr. Ricardo Gutiérrez", Buenos Aires, Argentina.



Background

- The insulin-like growth factors (IGFs) system are known to play an \checkmark important role in both normal and neoplastic growth.
- IGF2 overexpression has been identified in several cancers and was \checkmark significantly related to the initiation and progression of cancers.
- Gliomas are the most frequent solid tumours in paediatric patients. \checkmark

Aim

To characterize the expression and intracellular localization of IGF-2 in a large cohort of paediatric gliomas, and its association with clinical outcome.

Methods

Design: Prospective study of gliomas from paediatric patients that underwent surgery in our Hospital between August 2007 and April 2018. \checkmark

Gliomas were classified as low (LGG) and high grade (HGG) according to "2016 WHO classification of central nervous system tumours". \checkmark

Immunohistochemistry (IHC): IGF-2 intracellular expression and localization


- Using IGF2 antibody (Abcam Ab9574) in fixed tumour samples.

staining in citoplasmatic compartement.

Quantitation PCR (qPCR) : IGF2 gene expression


 \checkmark In those tumours where fresh sample were available.

 The results were classified according to IGF2 labeling in: Negative Positive : Cytoplasmatic Cytoplasmatic/nuclear 			out tumour tumour
		Results	
Total gliomas studied by IHC	Low grade n= 82	Total gliomas studied by qPCR	Low grade n= 37
	High grade n= 17		High grade n= 9
Sex (F/M)	F: 42 / M: 57	Sex (F/M)	F: 20 / M: 26
Age: medium ± SD (range)	8.24 ± 4.87 years (0.37 – 18.32)	Age: medium ± SD (range)	9.03 ± 4.82 years (0.87 – 18.32)
Follow-up: medium ± SD (range)	4.66 ± 2.21 years (0.27 – 11.81)	Follow-up: medium ± SD (range)	5.05 ± 1.43 years (1.65 – 7.22)
Gliomas localization	Supratentorial n=48	Gliomas localization	Supratentorial n=22
	Infratentorial n=46		Infratentorial n=23
	Intramedullary n=5		Intramedullary n=1
Clinical outcome	Alive without tumour n= 32	Clinical outcome	Alive without tumour n= 21
(7 drop-outs)	Alive with tumour n= 35	(5 drop-outs)	Alive with tumour n= 14
	Dead n = 17		Dead n = 6



p > 0,05 Chi² Test

Survival according IGF2 IHC labeling



Conclusions:

We are reporting the second tumour type presenting nuclear IGF2 intracellular localization and the first in the paediatric patients.

In contrast with results found in other tumours, IGF-2 intracellular localization performed by IHC does not correlate with clinical outcome in paediatric gliomas. However, the association between initial elevated IGF-2 mRNA levels with clinical outcome in low grade gliomas suggest a role for IGF2 in the biological behavior of these tumours.





